id
stringlengths 11
11
| tags
stringlengths 10
777
| text
stringlengths 2
1.5k
| dataset_num
int64 1
3
| tokens
list | ner_tags
list |
|---|---|---|---|---|---|
NCT02463305
|
9:32:treatment,46:66:treatment,,,150:161:treatment,163:175:treatment,177:193:treatment,
|
Allowed concomitant medications will include mesalamine compounds if used for at least 8 weeks and at a stable dose for at least 4 weeks, as well as thiopurines (azathioprine, 6-mercaptopurine) if used at a stable dose for at least 3 months
| 1
|
[
"Allowed",
"concomitant",
"medications",
"will",
"include",
"mesalamine",
"compounds",
"if",
"used",
"for",
"at",
"least",
"8",
"weeks",
"and",
"at",
"a",
"stable",
"dose",
"for",
"at",
"least",
"4",
"weeks",
",",
"as",
"well",
"as",
"thiopurines",
"(",
"azathioprine",
",",
"6-mercaptopurine",
")",
"if",
"used",
"at",
"a",
"stable",
"dose",
"for",
"at",
"least",
"3",
"months"
] |
[
0,
1,
1,
0,
0,
1,
1,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
0,
1,
0,
1,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT03107897
|
25:77:chronic_disease
|
Subject has significant severe un-revascularized epicardial coronary disease
| 1
|
[
"Subject",
"has",
"significant",
"severe",
"un-revascularized",
"epicardial",
"coronary",
"disease"
] |
[
0,
0,
0,
2,
2,
2,
2,
2
] |
NCT01515527
|
1:38:chronic_disease
|
psychiatric illness/social situations
| 1
|
[
"psychiatric",
"illness/social",
"situations"
] |
[
2,
2,
2
] |
NCT02312596
|
1:4:chronic_disease
|
HIV
| 1
|
[
"HIV"
] |
[
2
] |
NCT02564744
|
127:132:cancer
|
For Part 2 and Part 3 of the study, participants must have histopathologically and clinically confirmed diagnosis of relapsed DLBCL
| 1
|
[
"For",
"Part",
"2",
"and",
"Part",
"3",
"of",
"the",
"study",
",",
"participants",
"must",
"have",
"histopathologically",
"and",
"clinically",
"confirmed",
"diagnosis",
"of",
"relapsed",
"DLBCL"
] |
[
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
3
] |
NCT02688647
|
,48:51:chronic_disease,
|
Chronic use of N-acetylcysteine prescribed for IPF (> 600 mg/day)
| 1
|
[
"Chronic",
"use",
"of",
"N-acetylcysteine",
"prescribed",
"for",
"IPF",
"(",
">",
"600",
"mg/day",
")"
] |
[
0,
0,
0,
0,
0,
0,
2,
0,
0,
0,
0,
0
] |
NCT01532687
|
12:29:chronic_disease,31:59:chronic_disease,64:87:chronic_disease
|
History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess
| 1
|
[
"History",
"of",
"abdominal",
"fistula",
",",
"gastrointestinal",
"perforation",
",",
"or",
"intra-abdominal",
"abscess"
] |
[
0,
0,
2,
2,
0,
2,
2,
0,
0,
2,
2
] |
NCT03180398
|
26:49:cancer
|
Histologically confirmed prostate adenocarcinoma
| 1
|
[
"Histologically",
"confirmed",
"prostate",
"adenocarcinoma"
] |
[
0,
0,
3,
3
] |
NCT02340156
|
11:25:treatment
|
Requiring renal dialysis
| 1
|
[
"Requiring",
"renal",
"dialysis"
] |
[
0,
1,
1
] |
NCT02969187
|
1:13:treatment
|
hysterectomy
| 1
|
[
"hysterectomy"
] |
[
1
] |
NCT02931110
|
1:21:treatment
|
dabigatran etexilate
| 1
|
[
"dabigatran",
"etexilate"
] |
[
1,
1
] |
NCT02056873
|
23:30:chronic_disease,32:42:chronic_disease,44:60:chronic_disease,71:98:chronic_disease
|
Untreated or unstable anxiety, depression, bipolar disorder, or other Axis I psychiatric disorder
| 1
|
[
"Untreated",
"or",
"unstable",
"anxiety",
",",
"depression",
",",
"bipolar",
"disorder",
",",
"or",
"other",
"Axis",
"I",
"psychiatric",
"disorder"
] |
[
0,
0,
0,
2,
0,
2,
0,
2,
2,
0,
0,
0,
2,
2,
2,
2
] |
NCT02581982
|
18:27:chronic_disease
|
Known history of active TB
| 1
|
[
"Known",
"history",
"of",
"active",
"TB"
] |
[
0,
0,
0,
2,
2
] |
NCT02172651
|
29:38:treatment,,
|
Regular use of supplemental vitamin D totaling ≥ 2,000 IU/day in the past year
| 1
|
[
"Regular",
"use",
"of",
"supplemental",
"vitamin",
"D",
"totaling",
"≥",
"2,000",
"IU/day",
"in",
"the",
"past",
"year"
] |
[
0,
0,
0,
0,
1,
1,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT02040610
|
,,59:68:treatment
|
Patients with 2 or 3 risk factors will require a negative bone scan for eligibility
| 1
|
[
"Patients",
"with",
"2",
"or",
"3",
"risk",
"factors",
"will",
"require",
"a",
"negative",
"bone",
"scan",
"for",
"eligibility"
] |
[
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
1,
0,
0
] |
NCT01791543
|
1:33:chronic_disease,
|
Thrombotic myocardial infarction within the preceding two (2) months
| 1
|
[
"Thrombotic",
"myocardial",
"infarction",
"within",
"the",
"preceding",
"two",
"(",
"2",
")",
"months"
] |
[
2,
2,
2,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT02570984
|
1:27:chronic_disease
|
chronic pulmonary diseases
| 1
|
[
"chronic",
"pulmonary",
"diseases"
] |
[
2,
2,
2
] |
NCT02521493
|
,43:53:treatment,63:72:treatment,76:79:chronic_disease
|
Patients =< 30 days from the last dose of cytarabine used for treatment of TMD
| 1
|
[
"Patients",
"=",
"<",
"30",
"days",
"from",
"the",
"last",
"dose",
"of",
"cytarabine",
"used",
"for",
"treatment",
"of",
"TMD"
] |
[
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
0,
0,
1,
0,
2
] |
NCT02576301
|
16:26:treatment
|
Treatment with colchicine
| 1
|
[
"Treatment",
"with",
"colchicine"
] |
[
0,
0,
1
] |
NCT01966367
|
30:39:treatment
|
Approval for the use of this treatment protocol by the individual institution's Human Rights Committee must be obtained, in accordance with the institutional assurance policies of the U. S. Department of Health and Human Services
| 1
|
[
"Approval",
"for",
"the",
"use",
"of",
"this",
"treatment",
"protocol",
"by",
"the",
"individual",
"institution",
"'s",
"Human",
"Rights",
"Committee",
"must",
"be",
"obtained",
",",
"in",
"accordance",
"with",
"the",
"institutional",
"assurance",
"policies",
"of",
"the",
"U.",
"S.",
"Department",
"of",
"Health",
"and",
"Human",
"Services"
] |
[
0,
0,
0,
0,
0,
0,
1,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT01794559
|
12:22:treatment,24:43:cancer,45:69:chronic_disease,92:108:chronic_disease,110:126:chronic_disease,128:141:chronic_disease,143:168:chronic_disease,170:178:chronic_disease,180:198:chronic_disease,203:243:chronic_disease,255:273:treatment,
|
History of craniotomy, cerebral metastases, cerebrovascular accident, current diagnosis of seizure disorder, bipolar disorder, schizophrenia, schizo-affective disorder, dementia, mental retardation, or major depression with psychotic features, or use of depot neuroleptics in the last 12 months
| 1
|
[
"History",
"of",
"craniotomy",
",",
"cerebral",
"metastases",
",",
"cerebrovascular",
"accident",
",",
"current",
"diagnosis",
"of",
"seizure",
"disorder",
",",
"bipolar",
"disorder",
",",
"schizophrenia",
",",
"schizo-affective",
"disorder",
",",
"dementia",
",",
"mental",
"retardation",
",",
"or",
"major",
"depression",
"with",
"psychotic",
"features",
",",
"or",
"use",
"of",
"depot",
"neuroleptics",
"in",
"the",
"last",
"12",
"months"
] |
[
0,
0,
1,
0,
3,
3,
0,
2,
2,
0,
0,
0,
0,
2,
2,
0,
2,
2,
0,
2,
0,
2,
2,
0,
2,
0,
2,
2,
0,
0,
2,
2,
2,
2,
2,
0,
0,
0,
0,
1,
1,
0,
0,
0,
0,
0
] |
NCT02629120
|
1:4:chronic_disease
|
HIV positive
| 1
|
[
"HIV",
"positive"
] |
[
2,
0
] |
NCT02092324
|
1:20:chronic_disease
|
cardiac dysfunction
| 1
|
[
"cardiac",
"dysfunction"
] |
[
2,
2
] |
NCT02768727
|
27:51:treatment
|
History or current use of psychotropic medications
| 1
|
[
"History",
"or",
"current",
"use",
"of",
"psychotropic",
"medications"
] |
[
0,
0,
0,
0,
0,
1,
1
] |
NCT01928576
|
28:52:cancer
|
Patients with a history of carcinomatous meningitis are not eligible
| 1
|
[
"Patients",
"with",
"a",
"history",
"of",
"carcinomatous",
"meningitis",
"are",
"not",
"eligible"
] |
[
0,
0,
0,
0,
0,
3,
3,
0,
0,
0
] |
NCT00625417
|
1:28:treatment
|
excisional biopsy procedure
| 1
|
[
"excisional",
"biopsy",
"procedure"
] |
[
1,
1,
1
] |
NCT03158519
|
19:34:treatment,66:75:treatment,79:98:treatment,111:118:treatment,120:129:treatment,138:150:treatment,
|
Completion of all primary therapy (with the exception of ongoing endocrine or trastuzumab therapy), including surgery, radiation, and/or chemotherapy greater than 4 weeks prior to study enrollment
| 1
|
[
"Completion",
"of",
"all",
"primary",
"therapy",
"(",
"with",
"the",
"exception",
"of",
"ongoing",
"endocrine",
"or",
"trastuzumab",
"therapy",
")",
",",
"including",
"surgery",
",",
"radiation",
",",
"and/or",
"chemotherapy",
"greater",
"than",
"4",
"weeks",
"prior",
"to",
"study",
"enrollment"
] |
[
0,
0,
0,
1,
1,
0,
0,
0,
0,
0,
0,
1,
0,
1,
1,
0,
0,
0,
1,
0,
1,
0,
0,
1,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT02184520
|
10:19:treatment
|
Requires treatment of more than two vertebral levels
| 1
|
[
"Requires",
"treatment",
"of",
"more",
"than",
"two",
"vertebral",
"levels"
] |
[
0,
1,
0,
0,
0,
0,
0,
0
] |
NCT00358657
|
1:26:chronic_disease,
|
Cardiac ejection fraction < 30%
| 1
|
[
"Cardiac",
"ejection",
"fraction",
"<",
"30",
"%"
] |
[
2,
2,
2,
0,
0,
0
] |
NCT02101944
|
52:80:treatment,85:105:treatment,129:140:treatment,,191:221:treatment
|
Patients must have been previously treated with an immunomodulatory drug (IMiD) and proteasome inhibitor, must be refractory to carfilzomib defined as progression on or within 2 months of a carfilzomib-containing therapy, and must be progressing
| 1
|
[
"Patients",
"must",
"have",
"been",
"previously",
"treated",
"with",
"an",
"immunomodulatory",
"drug",
"(",
"IMiD",
")",
"and",
"proteasome",
"inhibitor",
",",
"must",
"be",
"refractory",
"to",
"carfilzomib",
"defined",
"as",
"progression",
"on",
"or",
"within",
"2",
"months",
"of",
"a",
"carfilzomib-containing",
"therapy",
",",
"and",
"must",
"be",
"progressing"
] |
[
0,
0,
0,
0,
0,
0,
0,
0,
1,
1,
1,
0,
0,
0,
1,
1,
0,
0,
0,
0,
0,
1,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
1,
0,
0,
0,
0,
0
] |
NCT02977299
|
,46:70:treatment
|
not responded to more than five FDA-approved antidepressant treatment trials of adequate dose and duration during the current episode, or who did not respond to ECT in previous episodes
| 1
|
[
"not",
"responded",
"to",
"more",
"than",
"five",
"FDA-approved",
"antidepressant",
"treatment",
"trials",
"of",
"adequate",
"dose",
"and",
"duration",
"during",
"the",
"current",
"episode",
",",
"or",
"who",
"did",
"not",
"respond",
"to",
"ECT",
"in",
"previous",
"episodes"
] |
[
0,
0,
0,
0,
0,
0,
0,
1,
1,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT02139436
|
1:9:chronic_disease
|
diabetes
| 1
|
[
"diabetes"
] |
[
2
] |
NCT02636530
|
8:23:treatment
|
use of glucocorticoids
| 1
|
[
"use",
"of",
"glucocorticoids"
] |
[
0,
0,
1
] |
NCT02253368
|
1:9:chronic_disease
|
diabetes
| 1
|
[
"diabetes"
] |
[
2
] |
NCT02400463
|
,,,99:108:treatment
|
all females of child-bearing potential must have a negative serum pregnancy test within 7 days of treatment
| 1
|
[
"all",
"females",
"of",
"child-bearing",
"potential",
"must",
"have",
"a",
"negative",
"serum",
"pregnancy",
"test",
"within",
"7",
"days",
"of",
"treatment"
] |
[
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1
] |
NCT02266329
|
52:62:treatment,52:63:treatment,64:74:treatment,,213:231:treatment,245:260:treatment,262:277:treatment,279:294:treatment,296:304:treatment,305:314:treatment,316:332:treatment,356:369:treatment,371:395:treatment,397:437:treatment,443:472:treatment
|
Subjects must be on a stable dose of the following medications/treatments for at least 4 weeks prior to the preliminary screening period, and must intend to continue the medication for the duration of the trial: psychoactive drugs, for example anticonvulsants, benzodiazepines, antidepressants, sedative/hypnotics; antihypertensive medications, including beta blockers, calcium channel blockers, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers; magnesium prescribed specifically for headache
| 1
|
[
"Subjects",
"must",
"be",
"on",
"a",
"stable",
"dose",
"of",
"the",
"following",
"medications/treatments",
"for",
"at",
"least",
"4",
"weeks",
"prior",
"to",
"the",
"preliminary",
"screening",
"period",
",",
"and",
"must",
"intend",
"to",
"continue",
"the",
"medication",
"for",
"the",
"duration",
"of",
"the",
"trial",
":",
"psychoactive",
"drugs",
",",
"for",
"example",
"anticonvulsants",
",",
"benzodiazepines",
",",
"antidepressants",
",",
"sedative/hypnotics",
";",
"antihypertensive",
"medications",
",",
"including",
"beta",
"blockers",
",",
"calcium",
"channel",
"blockers",
",",
"angiotensin",
"converting",
"enzyme",
"inhibitors",
",",
"and",
"angiotensin",
"receptor",
"blockers",
";",
"magnesium",
"prescribed",
"specifically",
"for",
"headache"
] |
[
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
0,
0,
0,
0,
0,
0,
0,
1,
1,
0,
0,
0,
1,
0,
1,
0,
1,
0,
1,
0,
1,
0,
0,
0,
1,
1,
0,
1,
1,
1,
0,
1,
1,
1,
1,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT02496208
|
1:23:chronic_disease
|
Malabsorption syndrome
| 1
|
[
"Malabsorption",
"syndrome"
] |
[
2,
2
] |
NCT02498535
|
37:46:treatment
|
Willing and able to comply with the treatment schedule and procedures
| 1
|
[
"Willing",
"and",
"able",
"to",
"comply",
"with",
"the",
"treatment",
"schedule",
"and",
"procedures"
] |
[
0,
0,
0,
0,
0,
0,
0,
1,
0,
0,
0
] |
NCT02419495
|
26:45:treatment
|
must be recovered from a prior major surgery
| 1
|
[
"must",
"be",
"recovered",
"from",
"a",
"prior",
"major",
"surgery"
] |
[
0,
0,
0,
0,
0,
1,
1,
1
] |
NCT02593123
|
1:35:cancer
|
Chronic myelogenous leukemia (CML)
| 1
|
[
"Chronic",
"myelogenous",
"leukemia",
"(",
"CML",
")"
] |
[
3,
3,
3,
3,
0,
0
] |
NCT02960763
|
23:47:chronic_disease,49:62:chronic_disease,64:88:chronic_disease,90:115:chronic_disease,117:136:chronic_disease
|
Lifetime diagnosis of bipolar I or II disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or current psychotic symptoms
| 1
|
[
"Lifetime",
"diagnosis",
"of",
"bipolar",
"I",
"or",
"II",
"disorder",
",",
"schizophrenia",
",",
"schizoaffective",
"disorder",
",",
"schizophreniform",
"disorder",
",",
"delusional",
"disorder",
",",
"or",
"current",
"psychotic",
"symptoms"
] |
[
0,
0,
0,
2,
2,
2,
2,
2,
0,
2,
0,
2,
2,
0,
2,
2,
0,
2,
2,
0,
0,
0,
0,
0
] |
NCT01962415
|
1:31:chronic_disease
|
Bare Lymphocyte Syndrome (BLS)
| 1
|
[
"Bare",
"Lymphocyte",
"Syndrome",
"(",
"BLS",
")"
] |
[
2,
2,
2,
2,
0,
0
] |
NCT03035890
|
13:37:chronic_disease
|
symptomatic congestive heart failure
| 1
|
[
"symptomatic",
"congestive",
"heart",
"failure"
] |
[
0,
2,
2,
2
] |
NCT02484300
|
11:18:chronic_disease,39:51:chronic_disease,87:96:chronic_disease,108:114:chronic_disease,117:122:chronic_disease,124:134:chronic_disease,146:154:chronic_disease,157:170:chronic_disease,172:187:chronic_disease,206:214:chronic_disease
|
Any known cardiac (apart from treated hypertension with acceptable drugs, see below), pulmonary (including asthma), renal, neurologic (including epilepsy), neuromuscular, hepatic disease, or patients with diabetes
| 1
|
[
"Any",
"known",
"cardiac",
"(",
"apart",
"from",
"treated",
"hypertension",
"with",
"acceptable",
"drugs",
",",
"see",
"below",
")",
",",
"pulmonary",
"(",
"including",
"asthma",
")",
",",
"renal",
",",
"neurologic",
"(",
"including",
"epilepsy",
")",
",",
"neuromuscular",
",",
"hepatic",
"disease",
",",
"or",
"patients",
"with",
"diabetes"
] |
[
0,
0,
2,
0,
0,
0,
0,
2,
0,
0,
0,
0,
0,
0,
0,
0,
2,
0,
0,
2,
0,
0,
2,
0,
2,
0,
0,
2,
0,
0,
2,
0,
2,
2,
0,
0,
0,
0,
2
] |
NCT02203513
|
27:56:cancer,,,,129:133:cancer,156:165:treatment
|
Patients enrolling in the triple negative breast cancer (ER-/PR-/Her2-) group, Cohort 3, must have a negative family history of HBOC syndrome, or negative gBRCA1/2m test
| 1
|
[
"Patients",
"enrolling",
"in",
"the",
"triple",
"negative",
"breast",
"cancer",
"(",
"ER-/PR-/Her2-",
")",
"group",
",",
"Cohort",
"3",
",",
"must",
"have",
"a",
"negative",
"family",
"history",
"of",
"HBOC",
"syndrome",
",",
"or",
"negative",
"gBRCA1/2m",
"test"
] |
[
0,
0,
0,
0,
3,
3,
3,
3,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
3,
0,
0,
0,
0,
1,
0
] |
NCT02764801
|
1:36:chronic_disease
|
unstable cardiopulmonary conditions
| 1
|
[
"unstable",
"cardiopulmonary",
"conditions"
] |
[
2,
2,
2
] |
NCT01985087
|
1:6:cancer,
|
Tumor o6-methylguanine-DNA-methyltransferase promoter methylation status must be determined
| 1
|
[
"Tumor",
"o6-methylguanine-DNA-methyltransferase",
"promoter",
"methylation",
"status",
"must",
"be",
"determined"
] |
[
3,
0,
0,
0,
0,
0,
0,
0
] |
NCT03072238
|
13:32:chronic_disease,44:63:chronic_disease,78:93:treatment
|
Any ongoing cardiac arrhythmias (including atrial fibrillation) that require medical therapy
| 1
|
[
"Any",
"ongoing",
"cardiac",
"arrhythmias",
"(",
"including",
"atrial",
"fibrillation",
")",
"that",
"require",
"medical",
"therapy"
] |
[
0,
0,
2,
2,
0,
0,
2,
2,
0,
0,
0,
1,
1
] |
NCT02501954
|
28:49:chronic_disease,51:66:chronic_disease,71:94:chronic_disease,
|
Patients with a history of myocardial infarction, unstable angina, or uncontrolled arrhythmia within 3 months from enrollment
| 1
|
[
"Patients",
"with",
"a",
"history",
"of",
"myocardial",
"infarction",
",",
"unstable",
"angina",
",",
"or",
"uncontrolled",
"arrhythmia",
"within",
"3",
"months",
"from",
"enrollment"
] |
[
0,
0,
0,
0,
0,
2,
2,
0,
2,
2,
0,
0,
2,
2,
0,
0,
0,
0,
0
] |
NCT01816152
|
7:20:chronic_disease
|
major organ failure
| 1
|
[
"major",
"organ",
"failure"
] |
[
0,
2,
2
] |
NCT02700451
|
1:18:chronic_disease
|
Renal dysfunction
| 1
|
[
"Renal",
"dysfunction"
] |
[
2,
2
] |
NCT01853163
|
21:45:treatment,
|
has participated in any other clinical trial within 30 days prior to enrolling in this study
| 1
|
[
"has",
"participated",
"in",
"any",
"other",
"clinical",
"trial",
"within",
"30",
"days",
"prior",
"to",
"enrolling",
"in",
"this",
"study"
] |
[
0,
0,
0,
1,
1,
1,
1,
0,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT01697293
|
1:18:treatment,
|
tamoxifen therapy or other hormonal agents should be discontinued at least 1 week before the patient is enrolled on this study
| 1
|
[
"tamoxifen",
"therapy",
"or",
"other",
"hormonal",
"agents",
"should",
"be",
"discontinued",
"at",
"least",
"1",
"week",
"before",
"the",
"patient",
"is",
"enrolled",
"on",
"this",
"study"
] |
[
1,
1,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT01809002
|
13:28:allergy_name,37:52:allergy_name,53:63:allergy_name
|
Allergic to Bovine products such as Bovine Collagen Nerve Cuff
| 1
|
[
"Allergic",
"to",
"Bovine",
"products",
"such",
"as",
"Bovine",
"Collagen",
"Nerve",
"Cuff"
] |
[
0,
0,
4,
4,
0,
0,
0,
0,
4,
4
] |
NCT02503358
|
48:66:treatment,86:95:treatment,119:131:treatment,142:163:treatment,165:177:treatment,179:189:treatment,191:202:treatment,204:214:treatment,216:225:treatment,227:237:treatment,239:248:treatment,253:263:treatment,281:291:treatment,293:306:treatment,308:317:treatment,319:328:treatment,333:343:treatment,421:432:treatment
|
Caution should be exercised when administering paclitaxel (Taxol) concomitantly with medicines known to inhibit (e.g. ketoconazole and other imidazole antifungals, erythromycin, fluoxetine, gemfibrozil, cimetidine, ritonavir, saquinavir, indinavir and nelfinavir) OR induce (e.g. rifampicin, carbamazepine, phenytoin, efavirenz and nevirapine) either CYP2C8 or CYP3A4. Based on the in vitro data and SimCYP simulations, selumetinib is considered unlikely to perpetrate clinically significant drug-drug interaction via inhibition or induction of CYP enzymes
| 1
|
[
"Caution",
"should",
"be",
"exercised",
"when",
"administering",
"paclitaxel",
"(",
"Taxol",
")",
"concomitantly",
"with",
"medicines",
"known",
"to",
"inhibit",
"(",
"e.g",
".",
"ketoconazole",
"and",
"other",
"imidazole",
"antifungals",
",",
"erythromycin",
",",
"fluoxetine",
",",
"gemfibrozil",
",",
"cimetidine",
",",
"ritonavir",
",",
"saquinavir",
",",
"indinavir",
"and",
"nelfinavir",
")",
"OR",
"induce",
"(",
"e.g",
".",
"rifampicin",
",",
"carbamazepine",
",",
"phenytoin",
",",
"efavirenz",
"and",
"nevirapine",
")",
"either",
"CYP2C8",
"or",
"CYP3A4",
".",
"Based",
"on",
"the",
"in",
"vitro",
"data",
"and",
"SimCYP",
"simulations",
",",
"selumetinib",
"is",
"considered",
"unlikely",
"to",
"perpetrate",
"clinically",
"significant",
"drug-drug",
"interaction",
"via",
"inhibition",
"or",
"induction",
"of",
"CYP",
"enzymes"
] |
[
0,
0,
0,
0,
0,
0,
1,
1,
0,
0,
0,
0,
1,
0,
0,
0,
0,
0,
0,
1,
0,
0,
1,
1,
0,
1,
0,
1,
0,
1,
0,
1,
0,
1,
0,
1,
0,
1,
0,
1,
0,
0,
0,
0,
0,
0,
1,
0,
1,
0,
1,
0,
1,
0,
1,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT02664909
|
12:22:chronic_disease
|
History of hemophilia
| 1
|
[
"History",
"of",
"hemophilia"
] |
[
0,
0,
2
] |
NCT02498535
|
1:12:treatment,
|
Chest x-ray within the last six (6) months
| 1
|
[
"Chest",
"x-ray",
"within",
"the",
"last",
"six",
"(",
"6",
")",
"months"
] |
[
1,
1,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT02392286
|
1:5:chronic_disease
|
AIDS or AIDS-defining illness
| 1
|
[
"AIDS",
"or",
"AIDS-defining",
"illness"
] |
[
2,
0,
0,
0
] |
NCT00906984
|
,19:28:treatment
|
within 15 days of treatment demonstrating
| 1
|
[
"within",
"15",
"days",
"of",
"treatment",
"demonstrating"
] |
[
0,
0,
0,
0,
1,
0
] |
NCT02542657
|
27:34:cancer,
|
Baseline marrow burden or myeloma of at least 30%
| 1
|
[
"Baseline",
"marrow",
"burden",
"or",
"myeloma",
"of",
"at",
"least",
"30",
"%"
] |
[
0,
0,
0,
0,
3,
0,
0,
0,
0,
0
] |
NCT02407028
|
7:19:chronic_disease
|
Fixed coagulopathy
| 1
|
[
"Fixed",
"coagulopathy"
] |
[
0,
2
] |
NCT02930018
|
15:47:chronic_disease
|
Patient has a severe or fatal comorbid illness that will prevent improvement or follow-up
| 1
|
[
"Patient",
"has",
"a",
"severe",
"or",
"fatal",
"comorbid",
"illness",
"that",
"will",
"prevent",
"improvement",
"or",
"follow-up"
] |
[
0,
0,
0,
2,
2,
2,
2,
2,
0,
0,
0,
0,
0,
0
] |
NCT02101034
|
38:41:chronic_disease,72:94:treatment,124:168:treatment
|
Phase I and Arm 1 of Phase II: Known HIV-positivity and on combination antiretroviral therapy because of the potential for pharmacokinetic interactions with PD 0332991
| 1
|
[
"Phase",
"I",
"and",
"Arm",
"1",
"of",
"Phase",
"II",
":",
"Known",
"HIV-positivity",
"and",
"on",
"combination",
"antiretroviral",
"therapy",
"because",
"of",
"the",
"potential",
"for",
"pharmacokinetic",
"interactions",
"with",
"PD",
"0332991"
] |
[
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
2,
0,
0,
0,
1,
1,
0,
0,
0,
0,
0,
1,
1,
1,
1,
1
] |
NCT02438995
|
,,214:223:treatment
|
will be informed as to the potential risk of procreation while participating in this research trial and will be advised that they must use effective contraception during and for a period of three months after the treatment period
| 1
|
[
"will",
"be",
"informed",
"as",
"to",
"the",
"potential",
"risk",
"of",
"procreation",
"while",
"participating",
"in",
"this",
"research",
"trial",
"and",
"will",
"be",
"advised",
"that",
"they",
"must",
"use",
"effective",
"contraception",
"during",
"and",
"for",
"a",
"period",
"of",
"three",
"months",
"after",
"the",
"treatment",
"period"
] |
[
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
0
] |
NCT01967823
|
113:123:cancer,158:175:treatment,184:190:treatment,207:216:treatment
|
Confirmation of ESO expression and pathology is not required in patients with definitive radiologic evidence of meningioma who are unresectable, and in whom radiation therapy without biopsy is the standard treatment
| 1
|
[
"Confirmation",
"of",
"ESO",
"expression",
"and",
"pathology",
"is",
"not",
"required",
"in",
"patients",
"with",
"definitive",
"radiologic",
"evidence",
"of",
"meningioma",
"who",
"are",
"unresectable",
",",
"and",
"in",
"whom",
"radiation",
"therapy",
"without",
"biopsy",
"is",
"the",
"standard",
"treatment"
] |
[
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
3,
0,
0,
0,
0,
0,
0,
0,
1,
1,
0,
1,
0,
0,
0,
1
] |
NCT02091141
|
33:68:treatment,,123:138:treatment,152:176:treatment
|
Administration of strong/potent cytochrome P3A4 (CYP3A4) inhibitors or inducers within 14 days prior to the first dose of study treatment and while on treatment with alectinib
| 1
|
[
"Administration",
"of",
"strong/potent",
"cytochrome",
"P3A4",
"(",
"CYP3A4",
")",
"inhibitors",
"or",
"inducers",
"within",
"14",
"days",
"prior",
"to",
"the",
"first",
"dose",
"of",
"study",
"treatment",
"and",
"while",
"on",
"treatment",
"with",
"alectinib"
] |
[
0,
0,
0,
1,
1,
1,
1,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
1,
1,
1,
0,
0,
0,
0
] |
NCT01967823
|
,,120:129:treatment
|
Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the treatment on the fetus or infant
| 1
|
[
"Women",
"of",
"child-bearing",
"potential",
"who",
"are",
"pregnant",
"or",
"breastfeeding",
"because",
"of",
"the",
"potentially",
"dangerous",
"effects",
"of",
"the",
"treatment",
"on",
"the",
"fetus",
"or",
"infant"
] |
[
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
0,
0,
0,
0,
0
] |
NCT01896921
|
1:37:chronic_disease,
|
Chronic active hepatitis B infection as defined by presence of HBsAg
| 1
|
[
"Chronic",
"active",
"hepatitis",
"B",
"infection",
"as",
"defined",
"by",
"presence",
"of",
"HBsAg"
] |
[
2,
2,
2,
2,
2,
0,
0,
0,
0,
0,
0
] |
NCT02341209
|
,88:189:treatment,193:226:treatment,271:279:cancer
|
Measurable disease in at least one target lesion in the skin or able to be assessed by radiographic examination with FDG-PET fluorodeoxyglucose possitron emission tomography (FDG-PET) scan or computarized tomography (CT) scan, or peripheral blood showing involvement of lymphoma
| 1
|
[
"Measurable",
"disease",
"in",
"at",
"least",
"one",
"target",
"lesion",
"in",
"the",
"skin",
"or",
"able",
"to",
"be",
"assessed",
"by",
"radiographic",
"examination",
"with",
"FDG-PET",
"fluorodeoxyglucose",
"possitron",
"emission",
"tomography",
"(",
"FDG-PET",
")",
"scan",
"or",
"computarized",
"tomography",
"(",
"CT",
")",
"scan",
",",
"or",
"peripheral",
"blood",
"showing",
"involvement",
"of",
"lymphoma"
] |
[
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
1,
1,
1,
1,
1,
1,
1,
1,
1,
0,
0,
0,
1,
1,
1,
1,
0,
0,
0,
0,
0,
0,
0,
0,
0,
3
] |
NCT01983462
|
12:56:chronic_disease
|
History of chronic obstructive pulmonary disease (COPD)
| 1
|
[
"History",
"of",
"chronic",
"obstructive",
"pulmonary",
"disease",
"(",
"COPD",
")"
] |
[
0,
0,
2,
2,
2,
2,
2,
0,
0
] |
NCT02323698
|
12:39:treatment
|
Undergoing concurrent physical therapy
| 1
|
[
"Undergoing",
"concurrent",
"physical",
"therapy"
] |
[
0,
1,
1,
1
] |
NCT02584244
|
,,,,,192:222:treatment
|
Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) starting the day entering the study, and for 60 days after injection of the imaging agent
| 1
|
[
"Women",
"of",
"child-bearing",
"potential",
"must",
"agree",
"to",
"use",
"adequate",
"contraception",
"(",
"hormonal",
"or",
"barrier",
"method",
"of",
"birth",
"control",
",",
"abstinence",
")",
"starting",
"the",
"day",
"entering",
"the",
"study",
",",
"and",
"for",
"60",
"days",
"after",
"injection",
"of",
"the",
"imaging",
"agent"
] |
[
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
1,
1,
1,
1
] |
NCT02543866
|
32:56:chronic_disease
|
Lack of intestinal carriage of ESC-R Enterobacteriaceae (negative selective stool culture for ESC-R Enterobacteriaceae)
| 1
|
[
"Lack",
"of",
"intestinal",
"carriage",
"of",
"ESC-R",
"Enterobacteriaceae",
"(",
"negative",
"selective",
"stool",
"culture",
"for",
"ESC-R",
"Enterobacteriaceae",
")"
] |
[
0,
0,
0,
0,
0,
2,
2,
0,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT03157713
|
13:22:chronic_disease
|
have active psychosis
| 1
|
[
"have",
"active",
"psychosis"
] |
[
0,
0,
2
] |
NCT02488057
|
1:23:chronic_disease
|
cardiovascular disease
| 1
|
[
"cardiovascular",
"disease"
] |
[
2,
2
] |
NCT02215096
|
20:48:treatment,54:58:treatment,60:63:treatment,67:114:treatment
|
Subjects must have prior enzalutamide treatment; Any PI3K, AKT or mammalian target of rapamycin (mTOR) inhibitors
| 1
|
[
"Subjects",
"must",
"have",
"prior",
"enzalutamide",
"treatment",
";",
"Any",
"PI3K",
",",
"AKT",
"or",
"mammalian",
"target",
"of",
"rapamycin",
"(",
"mTOR",
")",
"inhibitors"
] |
[
0,
0,
0,
1,
1,
1,
0,
0,
1,
0,
1,
0,
1,
1,
1,
1,
1,
1,
0,
0
] |
NCT01912612
|
24:44:chronic_disease
|
Clinically significant coagulation disorder
| 1
|
[
"Clinically",
"significant",
"coagulation",
"disorder"
] |
[
0,
0,
2,
2
] |
NCT02955537
|
23:50:chronic_disease,52:79:chronic_disease,90:113:chronic_disease
|
Previous diagnosis of acute myocardial infarction, angina (stable or unstable), or known coronary artery disease
| 1
|
[
"Previous",
"diagnosis",
"of",
"acute",
"myocardial",
"infarction",
",",
"angina",
"(",
"stable",
"or",
"unstable",
")",
",",
"or",
"known",
"coronary",
"artery",
"disease"
] |
[
0,
0,
0,
2,
2,
2,
0,
2,
2,
2,
2,
0,
0,
0,
0,
0,
2,
2,
2
] |
NCT01505569
|
,97:107:treatment
|
Minimum frozen PBSC of 4 x 106 CD34 cells/kg as 2 aliquots; i.e. 2 x 106 CD34 cells/kg for each transplant are mandatory
| 1
|
[
"Minimum",
"frozen",
"PBSC",
"of",
"4",
"x",
"106",
"CD34",
"cells/kg",
"as",
"2",
"aliquots",
";",
"i.e",
".",
"2",
"x",
"106",
"CD34",
"cells/kg",
"for",
"each",
"transplant",
"are",
"mandatory"
] |
[
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
0,
0
] |
NCT01059786
|
10:17:treatment,24:36:treatment,38:48:treatment,
|
No other therapy (i.e. chemotherapy, interferon) for 4 weeks prior to study entry
| 1
|
[
"No",
"other",
"therapy",
"(",
"i.e",
".",
"chemotherapy",
",",
"interferon",
")",
"for",
"4",
"weeks",
"prior",
"to",
"study",
"entry"
] |
[
0,
0,
1,
0,
0,
0,
1,
0,
1,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT02620579
|
1:12:chronic_disease,,
|
hypotension (resting systolic blood pressure below 90 mm Hg)
| 1
|
[
"hypotension",
"(",
"resting",
"systolic",
"blood",
"pressure",
"below",
"90",
"mm",
"Hg",
")"
] |
[
2,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT01011777
|
74:78:treatment,82:105:treatment,138:165:chronic_disease
|
Any degree of renal scarring at the time of screening as demonstrated by DMSA or MAG3 renal scintigraphy in the presence of any grade of vesicoureteral reflux (VUR)
| 1
|
[
"Any",
"degree",
"of",
"renal",
"scarring",
"at",
"the",
"time",
"of",
"screening",
"as",
"demonstrated",
"by",
"DMSA",
"or",
"MAG3",
"renal",
"scintigraphy",
"in",
"the",
"presence",
"of",
"any",
"grade",
"of",
"vesicoureteral",
"reflux",
"(",
"VUR",
")"
] |
[
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
0,
1,
1,
1,
0,
0,
0,
0,
0,
0,
0,
2,
2,
2,
0,
0
] |
NCT02465060
|
,85:94:treatment
|
patient must be off the drug for at least 5 half-lives prior to registration to the treatment step (Step 1, 3, 5, 7)
| 1
|
[
"patient",
"must",
"be",
"off",
"the",
"drug",
"for",
"at",
"least",
"5",
"half-lives",
"prior",
"to",
"registration",
"to",
"the",
"treatment",
"step",
"(",
"Step",
"1",
",",
"3",
",",
"5",
",",
"7",
")"
] |
[
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT02595372
|
17:53:cancer,,,
|
Newly diagnosed triple negative breast cancer (TNBC) clinical stage Ic, II, or III
| 1
|
[
"Newly",
"diagnosed",
"triple",
"negative",
"breast",
"cancer",
"(",
"TNBC",
")",
"clinical",
"stage",
"Ic",
",",
"II",
",",
"or",
"III"
] |
[
0,
0,
3,
3,
3,
3,
3,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT02058095
|
1:11:treatment,15:27:treatment,19:27:treatment,,76:91:treatment
|
Peritoneal or hemodialysis within 90 days or anticipation that dialysis or ultrafiltration of any form will be required during the study period
| 1
|
[
"Peritoneal",
"or",
"hemodialysis",
"within",
"90",
"days",
"or",
"anticipation",
"that",
"dialysis",
"or",
"ultrafiltration",
"of",
"any",
"form",
"will",
"be",
"required",
"during",
"the",
"study",
"period"
] |
[
1,
0,
1,
0,
0,
0,
0,
0,
0,
1,
0,
1,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT03001830
|
1:24:chronic_disease,8:24:chronic_disease,30:35:chronic_disease,39:42:chronic_disease,99:116:treatment
|
active hepatitis B or C, and HBsAg or HCV RNA viral load positivity, respectively or currently on antiviral therapy for hepatitis B or C
| 1
|
[
"active",
"hepatitis",
"B",
"or",
"C",
",",
"and",
"HBsAg",
"or",
"HCV",
"RNA",
"viral",
"load",
"positivity",
",",
"respectively",
"or",
"currently",
"on",
"antiviral",
"therapy",
"for",
"hepatitis",
"B",
"or",
"C"
] |
[
2,
2,
2,
2,
2,
0,
0,
2,
0,
2,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
1,
0,
0,
0,
0,
0
] |
NCT02285101
|
1:46:treatment
|
Prior treatment with arginine depleting agent
| 1
|
[
"Prior",
"treatment",
"with",
"arginine",
"depleting",
"agent"
] |
[
1,
1,
1,
1,
1,
1
] |
NCT02862938
|
19:31:treatment
|
Participant is on chemotherapy
| 1
|
[
"Participant",
"is",
"on",
"chemotherapy"
] |
[
0,
0,
0,
1
] |
NCT02641093
|
1:4:chronic_disease
|
HIV
| 1
|
[
"HIV"
] |
[
2
] |
NCT01947140
|
57:90:chronic_disease
|
Patients must have histologically confirmed relapsed or refractory Non-Hodgkin's lymphoma
| 1
|
[
"Patients",
"must",
"have",
"histologically",
"confirmed",
"relapsed",
"or",
"refractory",
"Non-Hodgkin",
"'s",
"lymphoma"
] |
[
0,
0,
0,
0,
0,
0,
0,
2,
2,
2,
0
] |
NCT03077243
|
18:35:treatment
|
Prior history of radiation therapy to the head and neck
| 1
|
[
"Prior",
"history",
"of",
"radiation",
"therapy",
"to",
"the",
"head",
"and",
"neck"
] |
[
0,
0,
0,
1,
1,
0,
0,
0,
0,
0
] |
NCT01623167
|
1:23:chronic_disease,,
|
Severe aplastic anemia characterized by Bone marrow cellularity less than 30 percent
| 1
|
[
"Severe",
"aplastic",
"anemia",
"characterized",
"by",
"Bone",
"marrow",
"cellularity",
"less",
"than",
"30",
"percent"
] |
[
2,
2,
2,
0,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT03162731
|
15:23:chronic_disease,25:49:chronic_disease,73:79:chronic_disease,80:85:chronic_disease
|
subjects with vitiligo, type I diabetes mellitus, or resolved childhood asthma/atopy would be an exception to this rule
| 1
|
[
"subjects",
"with",
"vitiligo",
",",
"type",
"I",
"diabetes",
"mellitus",
",",
"or",
"resolved",
"childhood",
"asthma/atopy",
"would",
"be",
"an",
"exception",
"to",
"this",
"rule"
] |
[
0,
0,
2,
0,
2,
2,
2,
2,
0,
0,
0,
0,
2,
0,
0,
0,
0,
0,
0,
0
] |
NCT03139227
|
,,47:59:treatment
|
Must be > 1 year from pregnancy, lactation or chemotherapy
| 1
|
[
"Must",
"be",
">",
"1",
"year",
"from",
"pregnancy",
",",
"lactation",
"or",
"chemotherapy"
] |
[
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1
] |
NCT01858168
|
36:60:cancer,115:118:cancer,123:145:cancer
|
Previously documented diagnosis of myelodysplastic syndrome (or any dysplastic leukocyte morphology suggestive of MDS) or acute myeloid leukemia
| 1
|
[
"Previously",
"documented",
"diagnosis",
"of",
"myelodysplastic",
"syndrome",
"(",
"or",
"any",
"dysplastic",
"leukocyte",
"morphology",
"suggestive",
"of",
"MDS",
")",
"or",
"acute",
"myeloid",
"leukemia"
] |
[
0,
0,
0,
0,
3,
3,
0,
0,
0,
0,
0,
0,
0,
0,
3,
0,
0,
3,
3,
3
] |
NCT03110107
|
1:17:treatment,,74:99:treatment,118:131:treatment
|
Cytotoxic agents, unless at least 4 weeks have elapsed from last dose of prior anti-cancer therapy and initiation of study therapy
| 1
|
[
"Cytotoxic",
"agents",
",",
"unless",
"at",
"least",
"4",
"weeks",
"have",
"elapsed",
"from",
"last",
"dose",
"of",
"prior",
"anti-cancer",
"therapy",
"and",
"initiation",
"of",
"study",
"therapy"
] |
[
1,
1,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
1,
1,
1,
0,
0,
0,
1,
1
] |
NCT02230189
|
8:27:treatment,
|
Use of Xolair (omalizumab) within the last 6 months
| 1
|
[
"Use",
"of",
"Xolair",
"(",
"omalizumab",
")",
"within",
"the",
"last",
"6",
"months"
] |
[
0,
0,
1,
1,
0,
0,
0,
0,
0,
0,
0
] |
NCT02446236
|
10:20:cancer,33:65:cancer,72:100:cancer,119:124:cancer,
|
A second malignancy, other than basal cell carcinoma of the skin or in situ carcinoma of the cervix (unless for other tumor type patient was treated with curative intent at least 2 years previously.)
| 1
|
[
"A",
"second",
"malignancy",
",",
"other",
"than",
"basal",
"cell",
"carcinoma",
"of",
"the",
"skin",
"or",
"in",
"situ",
"carcinoma",
"of",
"the",
"cervix",
"(",
"unless",
"for",
"other",
"tumor",
"type",
"patient",
"was",
"treated",
"with",
"curative",
"intent",
"at",
"least",
"2",
"years",
"previously",
".",
")"
] |
[
0,
0,
3,
0,
0,
0,
3,
3,
3,
3,
3,
3,
0,
0,
3,
3,
3,
3,
3,
0,
0,
0,
0,
3,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0,
0
] |
NCT02379156
|
20:43:allergy_name
|
Known allergies to midodrine hydrochloride
| 1
|
[
"Known",
"allergies",
"to",
"midodrine",
"hydrochloride"
] |
[
0,
0,
0,
4,
4
] |
NCT02624765
|
1:12:chronic_disease
|
tachycardia
| 1
|
[
"tachycardia"
] |
[
2
] |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.